Vetoquinol: Annual Sales 2023: €529 Million
Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) LURE, France, January 24, 2024--(BUSINESS WIRE)--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoqu...
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
80.15 | |
83.02 | |
- | |
82.91 | |
79.97 | |
77.5572-109.0957 | |
949 M | |
20.1003 | |
11 833 K | |
537 M | |
0 | |
0.0103 | |
0.941 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) LURE, France, January 24, 2024--(BUSINESS WIRE)--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoqu...
LURE, France, January 03, 2024--(BUSINESS WIRE)--Regulatory News: Vetoquinol (Paris:VETO) published its calendar of financial communication for 2024. January 24, 2024: 2023 Annual revenues (after ma...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: